Not Yet Recruiting A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping NCT07587242 Conditions Congenital, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DMD, +22 more Locations Not specified View Trial Details
Active, Not Recruiting Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort NCT06512376 Conditions Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, +5 more Locations Beijing Tiantan Hospital — Beijing, China View Trial Details
